1. Home
  2. CHRS vs HDRN Comparison

CHRS vs HDRN Comparison

Compare CHRS & HDRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.01

Market Cap

159.1M

Sector

Health Care

ML Signal

HOLD

Logo Hadron Energy Inc. Common Stock

HDRN

Hadron Energy Inc. Common Stock

HOLD

Current Price

$0.68

Market Cap

148.0M

Sector

Utilities

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHRS
HDRN
Founded
2010
2024
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Electric Utilities: Central
Sector
Health Care
Utilities
Exchange
Nasdaq
Nasdaq
Market Cap
159.1M
148.0M
IPO Year
2014
2024

Fundamental Metrics

Financial Performance
Metric
CHRS
HDRN
Price
$1.01
$0.68
Analyst Decision
Buy
Analyst Count
6
0
Target Price
★ $7.75
N/A
AVG Volume (30 Days)
★ 1.7M
96.3K
Earning Date
11-05-2026
11-08-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 472.00
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
$44.19
N/A
Revenue Next Year
$65.06
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.97
$0.63
52 Week High
$2.62
$2.67

Technical Indicators

Market Signals
Indicator
CHRS
HDRN
Relative Strength Index (RSI) 36.72 16.49
Support Level $0.97 N/A
Resistance Level $1.53 $2.03
Average True Range (ATR) 0.07 0.11
MACD -0.00 -0.04
Stochastic Oscillator 16.02 4.34

Price Performance

Historical Comparison
CHRS
HDRN

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

About HDRN Hadron Energy Inc. Common Stock

Hadron Energy Inc is a nuclear technology company focused on developing factory-fabricated, transportable 10 megawatt-electric (MWe) micro-modular reactors (MMRs) to meet the growing demand for clean, reliable, and affordable power. The company aims to deliver scalable, carbon-free energy solutions that can be rapidly deployed to power a variety of industries, including data centers, industrial facilities, remote communities, government installations and more. The market segments for its proprietary reactor, Hadron Halos, are Data Centers, Industrial Facilities and Heavy Manufacturing, Remote Communities and Critical Infrastructure, and Utilities and Distributed Energy.

Share on Social Networks: